AMINOSYN 3.5% W/ DEXTROSE 25% IN PLASTIC CONTAINER

Clinical safety rating: caution

Comprehensive clinical and safety monograph for AMINOSYN 3.5% W/ DEXTROSE 25% IN PLASTIC CONTAINER (AMINOSYN 3.5% W/ DEXTROSE 25% IN PLASTIC CONTAINER).

How it works

Aminosyn 3.5% with dextrose 25% provides amino acids for protein synthesis and dextrose as a carbohydrate calorie source, primarily to prevent protein catabolism and maintain nitrogen balance in patients requiring parenteral nutrition.

What the body does with it

Metabolism	Amino acids are metabolized primarily in the liver via transamination and deamination; dextrose undergoes glycolysis and subsequent oxidative metabolism.
Excretion	Renal excretion of amino acids and dextrose metabolites; urea nitrogen accounts for ~80% of nitrogen elimination. Biliary/fecal elimination is negligible for intact components.
Half-life	Amino acids: 0.5-2 hours (plasma clearance). Dextrose: 1.5-2 hours (glucose half-life in normoglycemic patients); clinically, infusion must be continuous to maintain steady state.
Protein binding	Amino acids: minimal (<10%), bound to albumin and globulins; dextrose: negligible binding.
Volume of Distribution	Amino acids: Vd = 0.15-0.3 L/kg (total body water). Dextrose: Vd = 0.2 L/kg (extracellular fluid). Clinical meaning: distributes primarily into lean body mass and extracellular spaces.
Bioavailability	Intravenous: 100%. Not administered via oral or other routes due to product formulation.
Onset of Action	Intravenous: Immediate (within minutes) for amino acid provision and dextrose infusion; plasma amino acid levels rise within 15-30 minutes.
Duration of Action	Duration of metabolic effect: 2-4 hours after cessation of infusion; must be continuously infused for sustained nutritional support.

Classification & Brands

Dosing & administration

Intravenous infusion: 500 mL to 1000 mL per day, typically at a rate not exceeding 3 mL/kg/hour. Adjusted based on metabolic needs and fluid status.

Dosage form	INJECTABLE
Renal impairment	Contraindicated in severe renal impairment (GFR < 30 mL/min) or dialysis due to risk of volume overload and electrolyte abnormalities. For moderate impairment (GFR 30-59 mL/min), reduce dose by 50% and monitor electrolytes.
Liver impairment	Child-Pugh Class A: No adjustment. Class B: Reduce dose by 50% and monitor ammonia levels. Class C: Avoid use due to risk of hepatic encephalopathy.
Pediatric use	Weight-based: 2-3 g amino acids/kg/day and 10-15 g dextrose/kg/day. Infuse at rate of 0.1-0.2 g dextrose/kg/hour initially, titrate to maintain blood glucose between 80-120 mg/dL.
Geriatric use	Reduce initial rate to 1-2 mL/kg/hour, monitor fluid balance closely due to increased risk of hypervolemia and renal impairment. Adjust based on GFR and cardiac function.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for AMINOSYN 3.5% W/ DEXTROSE 25% IN PLASTIC CONTAINER (AMINOSYN 3.5% W/ DEXTROSE 25% IN PLASTIC CONTAINER).

Breastfeeding	Both dextrose and amino acids are endogenous substances and are excreted into breast milk in small amounts. No M/P ratio available. Considered compatible with breastfeeding; use only if clearly needed and monitor infant for hyperglycemia.
Teratogenic Risk	No teratogenic risk data specific to this combination. Both components are essential nutrients; dextrose and amino acids are not teratogenic at standard doses. However, hyperglycemia from dextrose may be associated with congenital anomalies if glucose levels are poorly controlled. No trimester-specific risks identified.

Warnings & precautions

■ FDA Black Box Warning

Death may occur due to improper administration; must be used under medical supervision. Solutions are hypertonic and may cause severe complications if extravasation occurs.

Side Effect Profile

Serious Effects

Absolute Contraindications

["Severe hepatic disease with encephalopathy","Severe renal failure without dialysis","Hyperglycemia or diabetic ketoacidosis","Hypersensitivity to any component","Unstable cardiovascular status"]

Clinical Precautions

Precautions	["Risk of hyperglycemia, particularly in diabetic or stressed patients","Fluid overload in patients with cardiac or renal impairment","Electrolyte abnormalities requiring monitoring","Infection risk from catheter-related bloodstream infections","Osmotic diuresis with dextrose loads"]
Food/Dietary	No direct food interactions, but enteral intake should be coordinated if transitioning to oral feeding. Avoid high-sugar foods if hyperglycemia occurs.

Clinical Tips & Counseling

Drug interactions

Loading safety data…

AMINOSYN 3.5% W/ DEXTROSE 25% IN PLASTIC CONTAINER

Clinical safety rating: caution

Comprehensive clinical and safety monograph for AMINOSYN 3.5% W/ DEXTROSE 25% IN PLASTIC CONTAINER (AMINOSYN 3.5% W/ DEXTROSE 25% IN PLASTIC CONTAINER).

How it works

What the body does with it

Metabolism	Amino acids are metabolized primarily in the liver via transamination and deamination; dextrose undergoes glycolysis and subsequent oxidative metabolism.
Excretion	Renal excretion of amino acids and dextrose metabolites; urea nitrogen accounts for ~80% of nitrogen elimination. Biliary/fecal elimination is negligible for intact components.
Half-life	Amino acids: 0.5-2 hours (plasma clearance). Dextrose: 1.5-2 hours (glucose half-life in normoglycemic patients); clinically, infusion must be continuous to maintain steady state.
Protein binding	Amino acids: minimal (<10%), bound to albumin and globulins; dextrose: negligible binding.
Volume of Distribution	Amino acids: Vd = 0.15-0.3 L/kg (total body water). Dextrose: Vd = 0.2 L/kg (extracellular fluid). Clinical meaning: distributes primarily into lean body mass and extracellular spaces.
Bioavailability	Intravenous: 100%. Not administered via oral or other routes due to product formulation.
Onset of Action	Intravenous: Immediate (within minutes) for amino acid provision and dextrose infusion; plasma amino acid levels rise within 15-30 minutes.
Duration of Action	Duration of metabolic effect: 2-4 hours after cessation of infusion; must be continuously infused for sustained nutritional support.

Classification & Brands

Dosing & administration

Intravenous infusion: 500 mL to 1000 mL per day, typically at a rate not exceeding 3 mL/kg/hour. Adjusted based on metabolic needs and fluid status.

Dosage form	INJECTABLE
Renal impairment	Contraindicated in severe renal impairment (GFR < 30 mL/min) or dialysis due to risk of volume overload and electrolyte abnormalities. For moderate impairment (GFR 30-59 mL/min), reduce dose by 50% and monitor electrolytes.
Liver impairment	Child-Pugh Class A: No adjustment. Class B: Reduce dose by 50% and monitor ammonia levels. Class C: Avoid use due to risk of hepatic encephalopathy.
Pediatric use	Weight-based: 2-3 g amino acids/kg/day and 10-15 g dextrose/kg/day. Infuse at rate of 0.1-0.2 g dextrose/kg/hour initially, titrate to maintain blood glucose between 80-120 mg/dL.
Geriatric use	Reduce initial rate to 1-2 mL/kg/hour, monitor fluid balance closely due to increased risk of hypervolemia and renal impairment. Adjust based on GFR and cardiac function.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for AMINOSYN 3.5% W/ DEXTROSE 25% IN PLASTIC CONTAINER (AMINOSYN 3.5% W/ DEXTROSE 25% IN PLASTIC CONTAINER).

Breastfeeding	Both dextrose and amino acids are endogenous substances and are excreted into breast milk in small amounts. No M/P ratio available. Considered compatible with breastfeeding; use only if clearly needed and monitor infant for hyperglycemia.
Teratogenic Risk	No teratogenic risk data specific to this combination. Both components are essential nutrients; dextrose and amino acids are not teratogenic at standard doses. However, hyperglycemia from dextrose may be associated with congenital anomalies if glucose levels are poorly controlled. No trimester-specific risks identified.

Warnings & precautions

■ FDA Black Box Warning

Death may occur due to improper administration; must be used under medical supervision. Solutions are hypertonic and may cause severe complications if extravasation occurs.

Side Effect Profile

Serious Effects

Absolute Contraindications

["Severe hepatic disease with encephalopathy","Severe renal failure without dialysis","Hyperglycemia or diabetic ketoacidosis","Hypersensitivity to any component","Unstable cardiovascular status"]

Clinical Precautions

Precautions	["Risk of hyperglycemia, particularly in diabetic or stressed patients","Fluid overload in patients with cardiac or renal impairment","Electrolyte abnormalities requiring monitoring","Infection risk from catheter-related bloodstream infections","Osmotic diuresis with dextrose loads"]
Food/Dietary	No direct food interactions, but enteral intake should be coordinated if transitioning to oral feeding. Avoid high-sugar foods if hyperglycemia occurs.

Clinical Tips & Counseling

Drug interactions

Loading safety data…

Clinical Pearls	Monitor serum electrolytes, glucose, and renal function daily. Administer via central line due to high dextrose concentration (25%) to prevent thrombophlebitis. Use with caution in patients with renal impairment, heart failure, or hyperglycemia. Avoid rapid infusion to prevent osmotic diuresis. Check for allergies to corn products (dextrose source).
Patient Advice	This solution provides nutrition through a vein; report any swelling, pain, or redness at the infusion site. · You may need frequent blood tests to monitor your blood sugar, kidney function, and electrolyte levels. · Tell your healthcare provider if you have diabetes, kidney disease, or heart failure. · Do not stop the infusion abruptly; the rate will be adjusted gradually.